Maravai LifeSciences Holdings, Inc.

Good day ladies and gentlemen and welcome to the first quarter 2024 Marabai Life Sciences Earnings Conference Call. As a reminder, this call is being recorded. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session where participants are requested to limit themselves to one question and one follow-up. If you want to ask a question during this time, press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again. Thank you. I would like to now turn the call over to Debbie Hart, Head of Investor Relations. You may begin.

Good afternoon, everyone. Thanks for joining us on our first quarter 2024 earnings call. Our press release and the slides that accompany today's call are posted on our website and available at investors.moravai.com. As you can see on our agenda for today on slide two, Trey will first provide you with a business update, and Kevin will review our financial results and guidance. Drew Burch, President of Nucleic Acid Production, and Becky Buzio, our Chief Commercial Officer, will join the call for the question and answer session following the prepared remarks. During today's call, management will make forward-looking statements and refer to GAAP and non-GAAP financial measures. it is possible that actual results could differ from management's expectations. We refer you to slide three for more detail on forward-looking statements and our use of non-GAAP financial measures. Our just-issued press release provides reconciliations to the most directly comparable GAAP measures. Please also refer to Maravai's SEC filings for additional information on the risks and uncertainties that may impact our operating results performance, and financial condition. Now, I'll turn the call over to Trey.

Thank you, Deb, and good afternoon, everyone. We appreciate having you join us for our call today.